A 46-year-old woman underwent a cadaveric renal transplant. Three months later, she
developed diarrhoea, fresh rectal bleeding, and cervical lymphadenopathy. Renal biopsy
showed no evidence of rejection. Flexible sigmoidoscopy revealed multiple colonic
ulcers, with no active bleeding (Figure [1]). Biopsies showed post-transplant lymphoproliferative disorder (PTLD). The cells
were positive for Epstein-Barr virus (EBV) latent membrane protein, and positive for
CD20, CD23, Pax 5, and EBV DNA. Tacrolimus (Astellaf Pharma, Ireland) was discontinued
and anti-CD20 antibody treatment (rituximab; Roche, Basle, Switzerland) was started.
Figure 1 The descending colon on the initial endoscopy.
However, 3 weeks later, another episode of rectal bleeding occurred. Flexible sigmoidoscopy
showed necrotic, sloughy mucosa, with bleeding from multiple colonic ulcers (Figure [2]). An emergency laparotomy revealed numerous vasculitic areas on serosal surfaces
in the small and large bowel, corresponding to sites of bowel ulceration. Subtotal
colectomy with end ileostomy was carried out. Histopathological analysis of the specimen
confirmed EBV-associated PTLD. Despite continued anti-CD20 therapy, and inotropic/ventilatory
support in the intensive-care unit, the patient died 14 days postoperatively.
Figure 2 Findings at the second endoscopy.
PTLD is a complication of immunosuppression following organ transplantation. Eighty
percent of cases are associated with EBV [1]. Following renal transplantation in adults, the incidence of PTLD is 0.5 - 2.0 %
[2]. The time of onset depends on the organ transplanted and on the type and duration
of immunosuppression; with tacrolimus, the mean is 4 months [2]. Gastrointestinal tract involvement occurs in up to 20 % of cases of PTLD, due to
the presence of mucosa-associated lymphoid tissue [3]. The distal small bowel is most commonly affected [4]. Reducing immunosuppression (the risk of graft rejection should be considered),
if successful, usually results in improvement within 2 - 4 weeks. If this fails, a
high mortality rate of 50 - 90 % is reported [1]. Anti-B-cell antibodies can be used.
In conclusion, rectal bleeding and isolated gastrointestinal PTLD, as in this case,
are uncommon [5], but should be considered in post-transplant patients. The condition can be aggressive
and fatal despite treatment. Early endoscopy with biopsies for even mild nonspecific
symptoms of PTLD is therefore advised.
Endoscopy_UCTN_Code_CCL_1AD_2AZ
Endoscopy_UCTN_Code_CCL_1AD_2AJ
